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Safety and Efﬁcacy of Rivaroxaban in PatientsWith Cardiac Implantable
Electronic Devices: Observations From the ROCKET AF Trial
George C. Leef, MD; Anne S. Hellkamp, MS; Manesh R. Patel, MD; Richard C. Becker, MD; Scott D. Berkowitz, MD; G€unter Breithardt, MD;
Jonathan L. Halperin, MD; Graeme J. Hankey, MD; Werner Hacke, MD, PhD; Christopher C. Nessel, MD; Daniel E. Singer, MD;
Keith A.A. Fox, MB, ChB; Kenneth W. Mahaffey, MD; Jonathan P. Piccini, MD, MHS
Background-—Although implantation of cardiac implantable electronic devices (CIEDs) in patients receiving warfarin is well studied,
limited data are available on the use of oral factor Xa inhibitors in this setting.
Methods and Results-—Using data from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (n=14 264), we compared baseline
characteristics and clinical outcomes in patients with atrial ﬁbrillation randomized to rivaroxaban versus warfarin who did and did
not undergo CIED implantation or revision. In this post-hoc, postrandomization, on-treatment analysis, only the ﬁrst intervention
per patient was analyzed. During a median follow-up of 2.2 years, 453 patients (242 rivaroxaban group; 211 warfarin group)
underwent de novo CIED implantation (64.2%) or revision procedures (35.8%). Patients who received CIEDs were older, more likely
to be male, and more likely to have past myocardial infarction, but had similar stroke risk compared to patients who did not receive
CIEDs. Most patients who received a device had study drug interrupted for the procedure and did not receive bridging
anticoagulation. During the 30-day postprocedural period, 11 patients (4.55%) in the rivaroxaban group experienced bleeding
complications compared with 15 (7.13%) in the warfarin group. Thromboembolic complications occurred in 3 patients (1.26%) in
the rivaroxaban group and 1 (0.48%) in the warfarin group. Event rates were too low for formal hypothesis testing.
Conclusions-—Bleeding and thromboembolic events were low in both rivaroxaban- and warfarin-treated patients. Periprocedural
use of oral factor Xa inhibitors in CIED implantation requires further study in prospective, randomized trials.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00403767. ( J Am Heart Assoc. 2017;6:
e004663. DOI: 10.1161/JAHA.116.004663.)
Key Words: anticoagulation • atrial ﬁbrillation • cardiac resynchronization therapy • factor Xa inhibitor • implantable
cardioverter-deﬁbrillator • pacemaker • rivaroxaban • warfarin
A trial ﬁbrillation (AF) is accompanied by signiﬁcantmorbidity and mortality and often complicates the
management of other cardiovascular disorders.1–5 Many
patients with AF beneﬁt from systemic anticoagulation
therapy to reduce the risk of stroke.6–9 Warfarin has been
studied in patients who undergo cardiac implantable elec-
tronic device (CIED) procedures10–13; however, there are
limited data on the use and management of non-vitamin-K oral
anticoagulants (NOACs) in patients undergoing CIED
procedures.
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Observational data suggest that both interrupted and
uninterrupted NOAC treatment do not appear to be associ-
ated with excess bleeding or embolic complications compared
with uninterrupted warfarin during the periprocedural period
surrounding CIED implantation or revision.14–18 However,
these studies have included relatively small cohorts, focus
mostly on dabigatran, and usually reﬂect single-center
experience. There is much less clinical experience with oral
factor Xa inhibitors. Current practice for managing NOACs
during the periprocedural period is quite heterogeneous.19
Given that AF is a common comorbid condition in many
patients undergoing CIED surgery and NOAC utilization is
increasing, there is a need for more evidence surrounding
clinical outcomes of patients treated with NOACs who
undergo device implantation or revision.20
Methods
The design and results of the Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation (ROCKET AF) study have been published
previously.21,22 Brieﬂy, ROCKET AF was a double-blind,
double-dummy, international clinical trial that randomized
14 264 patients with nonvalvular AF at moderate-to-high risk
for stroke to ﬁxed-dose rivaroxaban or adjusted-dose warfarin
(target international normalized ratio [INR], 2.0–3.0) for
prevention of stroke and systemic embolism. The study
protocol recommended stopping warfarin/placebo 4 days
before a planned procedure and rivaroxaban/placebo 2 days
before. The point-of-care INR was recommended to be ≤1.5
before proceeding with any invasive procedure. Bridging
anticoagulation was allowed, but not mandatory. No speciﬁc
recommendation was made in the study protocol regarding
the time frame for resumption of anticoagulation postproce-
dure. All decisions regarding the timing of study drug
cessation and resumption were ultimately left to the discre-
tion of the managing physician.
Because of the interest in the impact of actual treatment
and outcomes, the on-treatment population (patients who
received at least 1 dose of study drug and were followed for
events while on study drug or within 2 days of last dose) was
used for this study (N=14 236).
Deﬁnition of Device Procedures
Patients were included in the CIED cohort if they met either of
the 2 following criteria: (1) underwent CIED implantation
during the study or (2) had a device at the time of
randomization and underwent a revision or replacement
procedure related to the device (eg, generator replacement,
lead revision, upgrade to cardiac resynchronization therapy,
etc) during the study. For the purposes of this analysis, CIED
refers to pacemakers, implantable cardioverter deﬁbrillators
(ICD), and cardiac resynchronization therapy devices. All
procedures were at the discretion of the managing physicians.
Outcomes
Outcomes of interest were events within 30 days after the
CIED procedure. The day of procedure was counted as day 1,
and events were included regardless of whether the patients
remained on study drug for the entire 30-day observation
period. The primary efﬁcacy end point was the occurrence of
stroke (ischemic and hemorrhagic) or systemic embolism.
Secondary efﬁcacy end points included a composite of stroke,
systemic embolism, vascular death, or myocardial infarction
(MI); vascular death; and all-cause death. The primary safety
end point was major or nonmajor clinically relevant (NMCR)
bleeding as deﬁned by the International Society on Thrombo-
sis and Haemostasis.23 Secondary safety end points included
major bleeding, NMCR bleeding, and any transfusion. These
outcomes were analyzed for the rivaroxaban versus warfarin
groups as well as for continuous versus interrupted oral
anticoagulation. For the purposes of this study, “continuous”
oral anticoagulation means that no doses of the study drug
were held or delayed.
Time in therapeutic range (TTR) was also analyzed for the
warfarin group at 30 and 90 days pre- and postprocedure and
compared with the TTR for the study as a whole. TTR was
calculated as the number of days with an INR between 2.0
and 3.0 (inclusive). INR values for days between measure-
ments were imputed with the Rosendaal method.24 Patients
were included in the 30- and 90-day pre- and postprocedure
categories only if they had actual or imputed INR values for at
least two thirds of the days in question. For the preprocedure
groups, patients were omitted if their procedure occurred too
soon after randomization to provide a sufﬁcient number of
days of INR values. For postprocedure groups, patients were
omitted if they stopped the study drug before the end of the
period in question. Exclusions described in this paragraph
apply to TTR summaries only.
Statistical Analysis
For description of rates of CIED-related procedures and
baseline characteristics of patients who did or did not
undergo CIED-related procedures, the cohort of all ROCKET
AF patients who received study drug was used. For exami-
nation of 30-day postprocedure outcomes, the cohort of
patients who underwent CIED-related procedures was used.
Only procedures that occurred during the on-treatment period
were counted. If a patient underwent more than 1
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CIED-related procedure during the study period, only the ﬁrst
procedure was included in this analysis. Baseline character-
istics were summarized as percent (frequency) for categorical
variables and as medians with 25th and 75th percentiles for
continuous variables, according to the occurrence of a CIED-
related procedure and the randomized treatment assignment.
For the comparison of patients who underwent CIED proce-
dures versus those with no CIED procedure, continuous
variables were compared with Wilcoxon rank-sum tests and
categorical variables were compared with Pearson chi-square
tests. Within the CIED procedure group, baseline character-
istics and events rates for patients in the rivaroxaban arm
were compared to those in the warfarin arm. Kaplan–Meier
30-day event rates were generated for outcomes. Because of
the low event rates, no hypothesis testing was performed to
compare these event rates among groups; these data are
presented in a descriptive fashion only, without correction for
postrandomization confounders.
The ROCKET AF study was coordinated by the Duke
Clinical Research Institute (Durham, NC). The Duke Clinical
Research Institute performed all statistical analyses indepen-
dent of the sponsors of the trial. The study was designed by
an international committee that took responsibility for the
accuracy and completeness of the analysis. All appropriate
national regulatory authorities and institutional ethical review
boards approved the study; all patients provided written
informed consent. All analyses were conducted using SAS
software (version 9.3 or higher; SAS Institute, Inc, Cary, NC).
Results
Cohort Characteristics
ROCKET AF enrolled 14 264 patients, of whom 14 236
received at least 1 dose of study drug. At time of enrollment,
1713 (12.0%) patients had a CIED. During a median follow-up
Table 1. CIED-Related Procedures During the Trial
All Randomized
Patients Rivaroxaban Warfarin
New device implant during the study
N (number of patients without a CIED at baseline) 12 523 6240 6283
Any implant 291 (2%) 152 (2%) 139 (2%)
Pacemaker 235 (2%) 129 (2%) 106 (2%)
ICD 35 (<1%) 17 (<1%) 18 (<1%)
Biventricular pacemaker-defibrillator 21 (<1%) 6 (<1%) 15 (<1%)
Time from randomization to surgery, months 9 (4, 16) 9 (4, 14) 10 (4, 17)
Procedures related to existing device
N (number of patients with a CIED at baseline) 1713 871 842
Any device-related procedure 162 (9%) 90 (10%) 72 (9%)
Pacemaker—N at baseline 1398 712 686
Procedure 115 (8%) 59 (8%) 56 (8%)
ICD—N at baseline 92 44 48
Procedure 10 (11%) 6 (14%) 4 (8%)
Biventricular pacemaker—N at baseline 223 115 108
Procedure 37 (17%) 25 (22%) 12 (11%)
Time from randomization to procedure, months 9 (5, 16) 10 (5, 18) 8 (5, 15)
Any CIED-related procedure (sum of sections above)
N (all randomized patients) 14 236 7111 7125
Any CIED-related procedure 453 (3%) 242 (3%) 211 (3%)
Pacemaker 350 (2%) 188 (3%) 162 (2%)
ICD 45 (<1%) 23 (<1%) 22 (<1%)
Biventricular pacemaker-defibrillator 58 (<1%) 31 (<1%) 27 (<1%)
Time from randomization to procedure, months 9 (4, 16) 10 (4, 16) 9 (5, 16)
Time variables are shown as median (25th, 75th percentiles). CIED indicates cardiac implantable electronic device; ICD, implantable cardioverter deﬁbrillator.
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of 2.2 years, 453 patients had a CIED-related procedure (3.2%
of the total cohort). Of the 453 CIED procedures, 242 were in
the rivaroxaban arm and 211 were in the warfarin arm
(Table 1). There were a total of 291 (64.2%) de novo CIEDs;
235 were pacemaker implants, 35 were ICDs, and 21 were
biventricular pacemaker or biventricular ICD implants. The
remaining 162 (35.8%) patients underwent procedures related
to existing devices. The majority of these were related to pre-
existing pacemakers (115). There were smaller numbers of
procedures on pre-existing ICDs (10) and biventricular devices
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Insufficient INR data‡
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Figure 1. Flow chart depicting all patients who underwent CIED procedures and exclusions from this
analysis. *Patients not receiving study drug—at any time or after permanent discontinuation—were
followed for efﬁcacy events only. Other events were occasionally, but not systematically, recorded. Thus, 28
patients who never received study drug are omitted from the analysis, because both postimplant device
status and safety (bleeding) events are unknown, and 4 patients who underwent a device-related procedure
(replacement) after the end of study drug are omitted because (1) it is unlikely they are a complete
accounting of device-related procedures during that period and (2) their safety event status is unknown.
†Violations in good clinical practice guidelines at 1 site made their efﬁcacy data unreliable; patients from
this site are omitted from all efﬁcacy analyses. Safety data were unaffected. ‡Patients were included in the
30 and 90 days pre- and postprocedure TTR summaries only if they had actual or imputed INR values for at
least two thirds of the days in question. For the preprocedure groups, patients were omitted if their
procedure occurred too soon after randomization to provide a sufﬁcient number of days of INR values. For
postprocedure groups, patients were omitted if they stopped the study drug before the end of the period in
question. CIED indicates cardiac implantable electronic devices; GCP, Good Clinical Practice; INR,
international normalized ratio; TTR, time in therapeutic range.
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Table 2. Baseline Characteristics for Patients Who Do
Versus Do Not Undergo CIED-Related Procedure
Variable
CIED-Related
Procedure
(N=453)
No CIED-
Related
Procedure
(N=13 783) P Value*
Randomized to
rivaroxaban
242 (53%) 6869 (50%) 0.13
Age, y 75 (69, 79) 73 (65, 78) <0.0001
Female 147 (32%) 5498 (40%) 0.0014
Race <0.0001
White 422 (93%) 11 436 (83%)
Black 6 (1%) 173 (1%)
Asian 16 (4%) 1765 (13%)
Other 9 (2%) 409 (3%)
Geographical
region
<0.0001
North America 193 (43%) 2480 (18%)
Western
Europe
73 (16%) 2016 (15%)
Eastern
Europe
117 (26%) 5376 (39%)
Latin America 45 (10%) 1832 (13%)
Asia/Pacific 25 (6%) 2079 (15%)
Type of AF 0.12
Persistent 352 (78%) 11 173 (81%)
Paroxysmal 96 (21%) 2415 (18%)
New onset 5 (1%) 195 (1%)
Time since AF
diagnosis, y
4.9 (1.4, 9.2) 3.2 (0.9, 7.1) <0.0001
CHADS2 score,
mean (SD)
3.5 (1.0) 3.5 (0.9) 0.50
CHADS2 score
1 0 (0) 3 (<1%)
2 65 (14%) 1790 (13%)
3 184 (41%) 6019 (44%)
4 125 (28%) 3960 (29%)
5 67 (15%) 1742 (13%)
6 12 (3%) 269 (2%)
Presenting characteristics
BMI, kg/m2 28.8 (25.8, 32.4) 28.1 (25.1, 32.0) 0.0090
Systolic blood
pressure,
mm Hg
130 (120, 140) 130 (120, 140) 0.0041
Diastolic
blood
pressure,
mm Hg
79 (70, 82) 80 (70, 85) <0.0001
Continued
Table 2. Continued
Variable
CIED-Related
Procedure
(N=453)
No CIED-
Related
Procedure
(N=13 783) P Value*
Heart rate,
beats/min
70 (62, 80) 76 (68, 86) <0.0001
Creatinine
clearance,†
mL/min
66 (51, 86) 67 (52, 87) 0.34
CIED at time of
randomization‡
0.0003
Pacemaker 115 (25%) 1283 (9%)
ICD 10 (2%) 82 (1%)
Biventricular
pacemaker
37 (8%) 186 (1%)
Baseline comorbidities
Past stroke/TIA/
embolism
206 (45%) 7588 (55%) <0.0001
Peripheral
artery
disease
38 (8%) 798 (6%) 0.021
Carotid occlusive
disease
25 (6%) 566 (4%) 0.14
Hypertension 418 (92%) 12 469 (90%) 0.20
Diabetes
mellitus
204 (45%) 5479 (40%) 0.024
Past MI 120 (26%) 2340 (17%) <0.0001
Congestive heart
failure
305 (67%) 8589 (62%) 0.030
COPD 61 (13%) 1432 (10%) 0.036
Medications
Past VKA use 347 (77%) 8542 (62%) <0.0001
Past chronic
ASA use
155 (34%) 5039 (37%) 0.31
ACE-inhibitor/ARB
at baseline
345 (76%) 10 238 (74%) 0.37
Beta-blocker
at baseline
308 (68%) 8942 (65%) 0.17
Digitalis at
baseline
136 (30%) 5332 (39%) 0.0002
Diuretic at
baseline
312 (69%) 8178 (59%) <0.0001
Data presented as n (%) or median (25th, 75th percentile), except where noted. ACE
indicates angiotensin-converting enzyme; AF, atrial ﬁbrillation; ARB, angiotensin receptor
blocker; ASA, acetylsalicylic acid; CIED, cardiac implantable electronic device; COPD,
chronic obstructive pulmonary disease; ICD, implantable cardioverter deﬁbrillator; MI,
myocardial infarction; TIA, transient ischemic attack; VKA, vitamin K antagonist.
*Continuous variables are compared with Wilcoxon rank-sum test and categorical
variables with Pearson chi-square tests.
†
Creatinine clearance calculated using the Cockcroft–Gault equation.
‡
For CIED type at baseline, percentages are among all patients in group; P value is for
difference in type among patients who have a device.
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(37). Four device-related procedures that occurred after
permanent discontinuation of the study drug were excluded
from this analysis (Figure 1). No other CIED implantation or
CIED-related procedure was excluded from our analysis.
Patients who underwent CIED-related procedures were, on
average, older, more often male and white, and more likely to
have past MI, but had similar CHA2DS2-VASc scores com-
pared to those who did not undergo CIED-related procedures
(Table 2). The rate of CIED procedures was highest among
patients randomized in North America (7.2%) or Western
Europe (3.5%), with lower rates in Eastern Europe (2.1%), Latin
America (2.4%), and Asia/Paciﬁc (1.2%). Baseline character-
istics of those undergoing CIED-related procedures were
similar regardless of treatment assignment (Table 3).
Management of Anticoagulation During the
Periprocedural Period
The majority of patients (341 [75%]) had study drug interrupted
for the procedure; however, 112 (25%) patients who under-
went procedures did not interrupt study drug. The number of
patients undergoing CIED procedures on uninterrupted anti-
coagulation was similar in the warfarin (57) and rivaroxaban
(55) groups. Most patients in whom oral anticoagulation was
interrupted for the procedure (299 [66%]) did not receive
bridging anticoagulation with a parenteral agent (Figure 2). A
small number (42) were treated with bridging anticoagulation,
usually low-molecular-weight heparin. As expected based on
protocol guidance, patients in the warfarin group were off oral
anticoagulation longer, with the study drug stopped at a
Table 3. Baseline Characteristics by Randomized Treatment
Among Patients Who Undergo CIED-Related Procedure
Variable
Rivaroxaban
(N=242)
Warfarin
(N=211)
Age, y 75 (69, 78) 75 (68, 80)
Female 75 (31%) 72 (34%)
Race
White 222 (92%) 200 (95%)
Black 3 (1%) 3 (1%)
Asian 11 (5%) 5 (2%)
Other 6 (2%) 3 (1%)
Geographical region
North America 106 (44%) 87 (41%)
Western Europe 39 (16%) 34 (16%)
Eastern Europe 55 (23%) 62 (29%)
Latin America 25 (10%) 20 (9%)
Asia/Pacific 17 (7%) 8 (4%)
Type of AF
Persistent 191 (79%) 161 (76%)
Paroxysmal 50 (21%) 46 (22%)
New onset 1 (<1%) 4 (2%)
Time since AF
diagnosis, y
5.1 (2.0, 9.6) 4.6 (1.0, 8.3)
CHADS2 score, mean (SD) 3.4 (1.0) 3.6 (1.0)
CHADS2 score
2 40 (17%) 25 (12%)
3 100 (41%) 84 (40%)
4 65 (27%) 60 (28%)
5 32 (13%) 35 (17%)
6 5 (2%) 7 (3%)
Presenting characteristics
BMI, kg/m2 28.7 (25.4, 32.8) 29.0 (26.3, 32.4)
Systolic blood
pressure, mm Hg
130 (120, 140) 130 (118, 140)
Diastolic blood
pressure, mm Hg
78 (70, 82) 79 (70, 82)
Heart rate, beats/min 70 (63, 80) 70 (61, 77)
Creatinine clearance,*
mL/min
68 (51, 91) 65 (50, 84)
Baseline comorbidities
Past stroke/TIA/embolism 111 (46%) 95 (45%)
Peripheral artery disease 19 (8%) 19 (9%)
Carotid occlusive disease 14 (6%) 11 (5%)
Hypertension 219 (90%) 199 (94%)
Diabetes mellitus 101 (42%) 103 (49%)
Continued
Table 3. Continued
Variable
Rivaroxaban
(N=242)
Warfarin
(N=211)
Past MI 62 (26%) 58 (27%)
Congestive heart failure 155 (64%) 150 (71%)
COPD 38 (16%) 23 (11%)
Medications
Past VKA use 186 (77%) 161 (76%)
Past chronic ASA use 84 (35%) 71 (34%)
ACE-inhibitor/ARB
at baseline
181 (75%) 164 (78%)
Beta-blocker at baseline 160 (66%) 148 (70%)
Digitalis at baseline 75 (31%) 61 (29%)
Diuretic at baseline 162 (67%) 150 (71%)
Data presented as n (%) or median (25th, 75th percentile), except where noted. ACE
indicates angiotensin-converting enzyme; AF, atrial ﬁbrillation; ARB, angiotensin receptor
blocker; ASA, acetylsalicylic acid; CIED, cardiac implantable electronic device; COPD,
chronic obstructive pulmonary disease; MI, myocardial infarction; TIA, transient ischemic
attack; VKA, vitamin K antagonist.
*Creatinine clearance calculated using the Cockcroft–Gault equation.
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median of 5 (25th, 75th percentiles: 3, 6) days before and
resumed at a median of 3 (1, 8) days after the procedure,
compared to a median of 3 (2, 6) days before and 2 (1, 5) days
after in the rivaroxaban group (Figure 2).
Time in Therapeutic Range
TTR for warfarin was calculated for 30 and 90 days pre- and
postprocedure (Table 4). TTR was markedly lower in the 30
days postprocedure versus 30 days preprocedure (43% vs
60%). The median TTR in the overall ROCKET AF trial was
58%,25 which is comparable with the TTR for the 30 days
preprocedure. Beyond the 90-day postprocedure period, the
TTR was comparable with that of the study overall (60%).
30-Day Postprocedure Outcomes
Adverse events during the postprocedural period were rare in
both rivaroxaban- and warfarin-treated patients (Table 5).
There were numerically more bleeding events in the warfarin-
versus rivaroxaban-treated patients (15 [7.13%] vs 11 [4.55%])
and, speciﬁcally, more pocket hematomas (6 [2.86%] vs 1
[0.41%]). There were numerically more strokes/systemic
embolic events in the rivaroxaban group versus the warfarin
group (3 [1.26%] vs 1 [0.48%]) and also more site infections
(3 [1.26%] vs 1 [0.49%]). Event rates were too low for any
formal hypothesis testing.
Incidence of stroke/systemic embolism (1.79% vs 0.59%)
and major/NMCR bleeding (6.28% vs 5.57%) were low among
patients who continued the study drug periprocedurally and in
those in whom the study drug was interrupted (Table 6).
Stroke/systemic embolism occurred in 0 patients who
received bridging anticoagulation versus 2 (0.68%) who did
not receive bridging. Major/NMCR bleeding occurred in 2
patients (4.82%) in the bridging group versus 17 (5.69%) in the
nonbridging group. However, the bridged group was very
small (42 patients), and patients with higher CHA2DS2-VASc
scores were more likely to have bridging anticoagulation with
low-weight-molecular heparin (Table 7).
Discussion
In a clinical trial of more than 14 000 patients with
nonvalvular AF and a relatively high prevalence of advanced
cardiovascular disease randomly assigned to receive rivarox-
aban or warfarin, 453 underwent CIED-related procedures
(242 rivaroxaban group, 211 warfarin group). In this analysis,
there were 2 major ﬁndings. First, there was substantial
variation in the management of oral anticoagulation during the
Figure 2. Study drug interruption and bridging therapy at the time of CIED-related procedure. CIED
indicates cardiac implantable electronic devices; LMWH, low-molecular-weight heparin; R, rivaroxaban; W,
warfarin.
Table 4. TTR for Warfarin Patients Who Undergo
CIED-Related Surgery
Time Period N TTR, %*
30 days preprocedure 193 60 (23, 100)
30 days postprocedure 171 43 (23, 73)
90 days preprocedure 185 58 (37, 78)
90 days postprocedure 173 60 (39, 75)
TTR indicates time in therapeutic range.
*Median (25th, 75th).
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periprocedural period for CIED implantations and revisions.
Second, the incidence of stroke or systemic embolism and
bleeding events in the 30 days following the procedure was
low in both the rivaroxaban and warfarin groups.
There was substantial heterogeneity in the management of
oral anticoagulation around the CIED procedures. The study
protocol recommended stopping warfarin/placebo 4 days
before and rivaroxaban/placebo 2 days before a planned
procedure. On average, both drugs were held for longer
preprocedure than recommended, but with considerable
variability. There was also considerable variability in the time
frame for resuming oral anticoagulation. There is not enough
evidence currently available to make a ﬁrm recommendation
on the optimal time frame for stopping rivaroxaban before a
procedure, but the current recommendation to stop rivarox-
aban 2 days in advance of a planned procedure seems
reasonable until stronger evidence is available.
Adverse events were uncommon in all groups during the
30 days postprocedure. Rates of stroke/systemic embolism
and bleeding complications were low in the rivaroxaban and
warfarin groups and comparable with other reports of invasive
procedures in patients maintained on oral anticoagulation,
aside from a slightly higher than expected rate of periproce-
dural thromboembolic complications in the rivaroxaban group.
Other analyses11,26–29 have consistently reported periproce-
dural stroke/systemic embolization rates in the 0.3% to 0.7%
range. This is consistent with the stroke rate in the warfarin
group in this analysis (0.48%). The stroke rate in the
rivaroxaban group was slightly higher (1.26%); however, this
may be an artifact of the small numbers in this study; there
were only 4 total thromboembolic events in our cohort. Two
previous ROCKET AF analyses looking at permanent discon-
tinuations of the study drug27 and therapeutic interruptions
from any cause28 reported stroke/systemic embolism rates in
the 0.3% to 0.7% range, which suggests that the higher stroke
rate in the rivaroxaban group here may be a statistical anomaly
attributable to small sample size. It seems unlikely that there is
an increased stroke risk with interrupted rivaroxaban, but
ideally this should be examined prospectively.
There were numerically fewer major or NMCR bleeds in
patients treated with rivaroxaban compared with warfarin (11
vs 15). It is unclear whether the increased lability in INR during
the immediate postprocedural period has any impact on event
rates given the low event rates. These data argue against a
major increase in bleeding risk with factor Xa inhibitors, but
the relative bleeding risks of warfarin versus rivaroxaban in
CIED procedures should be assessed in a prospective trial.
Although there were too few patients treated with bridging
anticoagulation in ROCKET AF to comment on this strategy, the
recent BRIDGE trial29 found that unbridged warfarin was
noninferior when compared with bridging with low-molecular-
weight heparin in a population of patients mostly at low-to-
moderate vascular risk. There are currently no comparable data
regarding NOACs and bridging with low-molecular-weight
heparin. The shorter half-life of the NOACs compared with
warfarin makes bridging anticoagulation less of a concern given
that patients are not subtherapeutic on their anticoagulation for
as long. Currently, there does not seem to be a compelling
rationale for bridging patients on rivaroxaban; however, this is
based largely on inference from the warfarin data. Ideally, this
would be investigated in a prospective manner.
Performing CIED procedures in patients on therapeutic
warfarin is supported by the most robust evidence base and is
the standard of care,10–13,29 but there is limited evidence
regarding procedures on continuous NOACs. Although this
strategy has limited clinical experience, continuous rivaroxa-
ban was used in 55 patients in ROCKET AF with few adverse
consequences and low event rates. These data do not suggest
a major increased risk with continuous rivaroxaban, but given
the differences between the continuous and interrupted oral
anticoagulant groups, this should be viewed as hypothesis
generating. The results of Strategy of Continued Versus
Interrupted Novel Oral Anti-coagulant at Time of Device
Table 5. Events in the 30 Days Following CIED-Related
Procedure, by Randomized Treatment
All Patients Rivaroxaban Warfarin
Efficacy end points
N 450* 239 211
Stroke/systemic
embolism
4 (0.89%) 3 (1.26%) 1 (0.48%)
Stroke/systemic
embolism/vascular
death/MI
7 (1.56%) 3 (1.26%) 4 (1.90%)
All-cause death 2 (0.44%) 1 (0.42%) 1 (0.47%)
Vascular death 1 (0.22%) 0 (0) 1 (0.47%)
Safety end points
N 453 242 211
Major or NMCR
bleeding
26 (5.75%) 11 (4.55%) 15 (7.13%)
Major bleeding 5 (1.11%) 3 (1.24%) 2 (0.95%)
NMCR bleeding 21 (4.64%) 8 (3.31%) 13 (6.18%)
Transfusion 2 (0.44%) 1 (0.41%) 1 (0.47%)
Hematoma at
surgical site†
7 (1.56%) 1 (0.41%) 6 (2.86%)
Infection at
surgical site
4 (0.90%) 3 (1.26%) 1 (0.49%)
Thirty-day Kaplan–Meier rates are shown, with total number of events. CIED indicates
cardiac implantable electronic device; MI, myocardial infarction; NMCR, nonmajor
clinically relevant.
*Efﬁcacy events were excluded for patients from a single good clinical practice-violating
site, so the N for efﬁcacy end points is slightly smaller than the N for safety end points.
†
Six of the 7 hematomas (the 1 in rivaroxaban patients and 5 of the 6 in warfarin
patients) were adjudicated as NMCR.
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Surgery in Patients With Moderate to High Risk of Arterial
Thromboembolic Events (BRUISE CONTROL-2),30 an upcoming
open-label trial that will randomize patients with nonvalvular
AF requiring a CIED procedure to continued or interrupted
NOAC, will offer additional insight into this strategy. Perform-
ing CIED procedures on uninterrupted NOACs may turn out to
be the superior strategy; however, at present there is
insufﬁcient evidence to support routine use of uninterrupted
NOACs during CIED procedures.
There are several limitations to this study. First, this was a
post-hoc analysis with no adjustment for postrandomization
confounders. If randomization to rivaroxaban versus warfarin
changed the odds of needing a CIED, that would skew the
results. Second, there was no speciﬁed time frame for
resuming anticoagulation after a procedure, and the speciﬁed
time frame for stopping before the procedure was not
consistently followed. Third, patients likely to need a CIED
may have had it implanted before enrollment in the trial, which
would affect the generalizability to all CIED patients. Finally,
and most important, the fairly small numbers of CIED-related
procedures and the low rates of adverse events limit the power
to detect a potentially signiﬁcant difference in event rates.
Conclusions
Patients in ROCKET AF who underwent CIED implantation or
revision while on rivaroxaban had low rates of stroke and
bleeding. Although current evidence is too limited to make
evidence-based recommendations, an interrupted and
unbridged rivaroxaban strategy appears reasonable for
patients maintained on rivaroxaban who require a CIED
procedure. This was the strategy used in the majority of CIED
procedures in the ROCKET AF trial and was associated with a
low rate of adverse events. It is too early to say whether a
continuous rivaroxaban strategy might be superior to inter-
rupted rivaroxaban; that approach will have to be further
evaluated in future prospective studies. These results do not
suggest a safety difference between warfarin and rivaroxaban;
however, they should be viewed as hypothesis generating.
There are still many questions regarding the optimal strategy
for managing factor Xa inhibitors around planned procedures.
These questions should be studied in future prospective trials
of factor Xa inhibitors in patients undergoing cardiac device
Table 6. Events in the 30 Days Following CIED-Related Procedure, by Study Drug Status and Bridging Therapy
On Study
Drug
Off Study
Drug
Bridging
Therapy
No Bridging
Therapy
Efficacy end points
N 112 338 42 296
Stroke/systemic embolism 2 (1.79%) 2 (0.59%) 0 (0) 2 (0.68%)
Stroke/systemic embolism/vascular
death/MI
3 (2.68%) 4 (1.18%) 0 (0) 4 (1.35%)
All-cause death 1 (0.89%) 1 (0.30%) 1 (2.38%) 0 (0)
Vascular death 1 (0.89%) 0 (0) 0 (0) 0 (0)
Safety end points
N 112 341 42 299
Major or NMCR bleeding 7 (6.28%) 19 (5.57%) 2 (4.82%) 17 (5.69%)
Major bleeding 1 (0.90%) 4 (1.17%) 0 (0) 4 (1.34%)
NMCR bleeding 6 (5.38%) 15 (4.40%) 2 (4.82%) 13 (4.35%)
Transfusion 1 (0.90%) 1 (0.29%) 0 (0) 1 (0.33%)
Hematoma at surgical site 3 (2.74%) 4 (1.18%) 0 (0) 4 (1.34%)
Infection at surgical site 1 (0.92%) 3 (0.89%) 0 (0) 3 (1.02%)
Thirty-day Kaplan–Meier rates are shown, with total number of events. CIED indicates cardiac implantable electronic device; MI, myocardial infarction; NMCR, nonmajor clinically relevant.
Table 7. Rates of Periprocedural Anticoagulation by
CHA2DS2-VASc Score
CHA2DS2-Vasc Score N
Any
Anticoagulation
During
Procedure
Uninterrupted
Study Drug
Off Study
Drug With
Bridging
Therapy
All patients in cohort
2 to 4 174 52 (30%) 42 (24%) 10 (6%)
≥5 279 102 (37%) 70 (25%) 32 (11%)
Patients with persistent AF
2 to 4 138 37 (27%) 30 (22%) 7 (5%)
≥5 214 78 (36%) 53 (25%) 25 (12%)
AF indicates atrial ﬁbrillation.
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placement, with more-deﬁned rules for whether to use
bridging anticoagulation and how long to hold the drug
before/after the procedure.
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